GlaxoSmithKline Consumer Healthcare Limited announces results for the quarter and full year ended March 31, 2017

   Sales rise by 1.1%; Profits up by 8% for the fourth quarter ended March 31, 2017

        Board of Directors of the Company recommended a Dividend at the rate of Rs. 70 per equity share of Rs. 10 each for the 12 month period ended March 31, 2017

                                                                                                  
  by Shrutee K /DNS

Gurugram, 11 May, 2017: GlaxoSmithKline Consumer Healthcare Limited today declared its financial results for the fourth quarter and full year ended March 31, 2017. The fourth quarter recorded good performance with sales at Rs. 1,149 crores increase of 1.1% and PBT at Rs. 269 crores increase by 8% compared to last year for the same period. For the full year, the reported sales at Rs. 4,209 crores decrease by 3.5% on account of demonetisation and PBT at Rs. 1,010 crores decrease by 4% compared to last year

The Board of Directors of the Company recommended a Dividend at the rate of Rs. 70 per equity share of Rs. 10 each for the 12 month period ended March 31, 2017.

Commenting on the results, Manoj Kumar, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “The fourth quarter has delivered positive results for the company. We continue to remain the market leader in Health Food Drinks category. Our access strategy, with re-launch of Rs. 5 pack of base Horlicks and Boost has enabled deep penetration and has uptake. Our recently launched awareness campaign around micronutrient deficiency^**, based on a study that found that up to 9 in 10 children's diets could be deficient in essential nutrients has been well received. We are confident that our high science based Horlicks portfolio will help address this.”

Performance Highlights:

·         Horlicks’ launched a new campaign around micronutrient deficiency, based on a study that found that up to 9 in 10 children's diets could be deficient in essential nutrients* that Horlicks can help overcome.

·         Boost launched a new thematic with Virat Kohli - ‘Play the Bigger Game’ that single-mindedly aimed at ‘Driving Connect with Kids’

Health Food Drinks – Market share

·         Our health food drink portfolio continues to be the market leader with 56.3%(Value share) and 64.4% (Volume share) – (MAT Mar, 2017)

·         Horlicks at 44.8% Value share and 50.6% Volume share (MAT Mar, 2017)

·         Boost at 11.2 % Value share and 13.5% Volume share (MAT Mar, 2017)

^*Iron, Vit. B1, B2, B3, B12, A & Folate. Krishnaswamy GJ et. al, Adequacy of Nutrient Intakes In Urban School Children. Poster (CMN-P-053) presented at: Nutrition Risk Management and Nutrition. 48th Annual National Conference of Nutrition Society of India; 4th – 5th November 2016, Bengaluru, India.

^**Micronutrient deficiency, also known as hidden hunger, is the key underlining issue and can be explained as inadequate intake of crucial vitamins and minerals ‒ such as zinc, vitamin A and folate ‒ which are needed for healthy mental and physical growth of children.

About GlaxoSmithKline Consumer Healthcare Ltd

GSK Consumer Healthcare Ltd is the category leader in Indian health food drinks industry. Our flagship product Horlicks leads the market, while Boost is among the top three health food drink brands that India prefers. Our manufacturing plants are located in Nabha, Rajahmundry and Sonepat. In India we have an engaged workforce of over 4000 employees. GSK also markets and distributes a range of everyday health products such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 700 distributors and a direct coverage of over 8 lakh retail outlets.

GSK Consumer Healthcare Ltd is an associate of GlaxoSmithKline plc. of U.K, one of world’s largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products.  Our goal is to build a global, growing business - we call a Fast Moving Consumer Healthcare (FMCH) company - dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.

GSK Consumer Healthcare globally owns some of the world’s best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Voltaren, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel.